BR112013003590A2 - método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b - Google Patents

método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b

Info

Publication number
BR112013003590A2
BR112013003590A2 BR112013003590A BR112013003590A BR112013003590A2 BR 112013003590 A2 BR112013003590 A2 BR 112013003590A2 BR 112013003590 A BR112013003590 A BR 112013003590A BR 112013003590 A BR112013003590 A BR 112013003590A BR 112013003590 A2 BR112013003590 A2 BR 112013003590A2
Authority
BR
Brazil
Prior art keywords
alpha
cells
receptor agonists
adrenergic receptor
activating regulatory
Prior art date
Application number
BR112013003590A
Other languages
English (en)
Inventor
Daniel W Gil
John E Donello
Lauren M B Luhrs
Veena Vishwanath
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013003590A2 publication Critical patent/BR112013003590A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b. é descrito aqui um método de super-regular células t regulatóriais, e tratar doenças que se beneficiariam de tal super-regulação, administrando um agonista de receptor alfa 2.
BR112013003590A 2010-08-16 2011-08-11 método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b BR112013003590A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37412410P 2010-08-16 2010-08-16
PCT/US2011/047426 WO2012024161A1 (en) 2010-08-16 2011-08-11 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
BR112013003590A2 true BR112013003590A2 (pt) 2016-05-31

Family

ID=44543836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003590A BR112013003590A2 (pt) 2010-08-16 2011-08-11 método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b

Country Status (18)

Country Link
US (5) US8575207B2 (pt)
EP (2) EP3332782A1 (pt)
JP (3) JP5938407B2 (pt)
KR (3) KR102013086B1 (pt)
CN (3) CN108272797B (pt)
AU (1) AU2011292296B2 (pt)
BR (1) BR112013003590A2 (pt)
CA (1) CA2808307C (pt)
DK (1) DK2605771T3 (pt)
ES (1) ES2676194T3 (pt)
HK (2) HK1256823A1 (pt)
HU (1) HUE038366T2 (pt)
PL (1) PL2605771T3 (pt)
PT (1) PT2605771T (pt)
RU (2) RU2016134989A (pt)
SI (1) SI2605771T1 (pt)
TR (1) TR201809456T4 (pt)
WO (1) WO2012024161A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014332A1 (en) * 2009-07-30 2011-02-03 Allergan, Inc. Selective alpha 2b/2c agonists
PT2605771T (pt) 2010-08-16 2018-07-09 Allergan Inc Método de ativação de células t reguladoras com agonistas dos recetores adrenérgicos alfa-2b
US20150313896A1 (en) * 2013-07-26 2015-11-05 Galderma Research & Development Method for treating cell proliferation disorders
RU2691412C2 (ru) * 2015-02-24 2019-06-13 Дзе Боард Оф Трастис Оф Дзе Юниверсити Оф Иллинойс Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US20180250369A1 (en) * 2015-09-11 2018-09-06 Ventria Bioscience, Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
WO2017062491A1 (en) * 2015-10-05 2017-04-13 Jing-Feng Huang Therapeutic compositions for the treatment of dry eye and related ocular surface diseases
EP3445372A4 (en) * 2016-04-22 2020-03-25 Viking Therapeutics, Inc. USE OF BETA-AGONISTS OF THYROID HORMONES
JP2020523406A (ja) 2017-05-19 2020-08-06 オクジェン アイエヌシー． 眼科用組成物および使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2835423A1 (de) 1978-08-12 1980-03-06 Hoechst Ag Beton- und moertelzusatzmittel und dessen verwendung
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
BRPI0414277A (pt) 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
AU2005290075A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
KR101202066B1 (ko) * 2004-09-28 2012-11-15 알러간, 인코포레이티드 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
AU2007332641A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
MX2010001351A (es) 2007-08-03 2010-06-25 Mill Steel Co Aparato para determinar el perfil de calibre para material enrollado plano.
WO2009020578A1 (en) 2007-08-06 2009-02-12 Schering Corporation Alpha2c adrenoreceptor agonists
WO2009052075A2 (en) 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US8809379B2 (en) * 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
BRPI0906875A2 (pt) * 2008-01-18 2015-07-07 Allergan Inc Agentes adrenérgicos alfa 2 de subtipo seletivo de oxazolidina e tiazolidina e métodos para uso dos mesmos
US8063231B2 (en) 2008-06-09 2011-11-22 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
ES2672777T3 (es) * 2008-06-09 2018-06-18 Allergan, Inc. Métodos de tratamiento de estados con mediación alfa-adrenérgica
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
WO2011014332A1 (en) 2009-07-30 2011-02-03 Allergan, Inc. Selective alpha 2b/2c agonists
PT2605771T (pt) 2010-08-16 2018-07-09 Allergan Inc Método de ativação de células t reguladoras com agonistas dos recetores adrenérgicos alfa-2b

Also Published As

Publication number Publication date
US20180071259A1 (en) 2018-03-15
JP6250728B2 (ja) 2017-12-20
RU2016134989A (ru) 2018-12-11
US20120041031A1 (en) 2012-02-16
WO2012024161A1 (en) 2012-02-23
CA2808307C (en) 2022-06-21
KR20130108301A (ko) 2013-10-02
PL2605771T3 (pl) 2018-10-31
ES2676194T3 (es) 2018-07-17
US20160158199A1 (en) 2016-06-09
EP2605771B1 (en) 2018-04-04
EP3332782A1 (en) 2018-06-13
JP5938407B2 (ja) 2016-06-22
EP2605771A1 (en) 2013-06-26
JP2013534246A (ja) 2013-09-02
CN114073696A (zh) 2022-02-22
CA2808307A1 (en) 2012-02-23
JP2016117781A (ja) 2016-06-30
DK2605771T3 (en) 2018-07-16
US10251865B2 (en) 2019-04-09
TR201809456T4 (tr) 2018-07-23
CN108272797A (zh) 2018-07-13
KR20190097323A (ko) 2019-08-20
PT2605771T (pt) 2018-07-09
US9545394B2 (en) 2017-01-17
CN103153296B (zh) 2018-02-13
AU2011292296A1 (en) 2013-03-14
US8575207B2 (en) 2013-11-05
CN108272797B (zh) 2021-04-27
AU2011292296B2 (en) 2015-09-03
US9289420B2 (en) 2016-03-22
SI2605771T1 (sl) 2018-09-28
JP2018027984A (ja) 2018-02-22
RU2016134989A3 (pt) 2020-02-17
CN103153296A (zh) 2013-06-12
KR102013086B1 (ko) 2019-08-21
US20170079956A1 (en) 2017-03-23
KR20180040710A (ko) 2018-04-20
HUE038366T2 (hu) 2018-10-29
RU2013110877A (ru) 2014-09-27
US20140066483A1 (en) 2014-03-06
RU2599495C2 (ru) 2016-10-10
HK1258043A1 (zh) 2019-11-01
KR101847669B1 (ko) 2018-05-24
HK1256823A1 (zh) 2019-10-04
JP6509307B2 (ja) 2019-05-08

Similar Documents

Publication Publication Date Title
BR112013003590A2 (pt) método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b
CO6440523A2 (es) Análogos de esfingosina-1-fosfato de arilo bicíclico
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX2021015850A (es) Agonista beta adrenergico y metodos de uso del mismo.
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
TN2011000272A1 (en) Dosage regimen for a s1p agonist
IN2013DN02552A (pt)
BR112012009891A2 (pt) métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
MX352727B (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
UY32853A (es) Nuevos compuestos de oxadiazol
EA200901619A1 (ru) Способ получения телмисартана
DOP2014000098A (es) 2-tiopirimidinonas
CO2018004473A2 (es) Compuestos agonistas de ppar y composiciones farmaceuticas
CL2013000733A1 (es) Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
BR112015008143A2 (pt) complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112018015389A2 (pt) derivado de 5-etil-4-metil-pirazol-3-carboxamida tendo atividade como agonista de taar
BR112015012778A2 (pt) estrutura de suporte de componente de escapamento
EA201291446A1 (ru) Композиции для ухода за кожей, содержащие замещенные моноамины
BR112015026259A2 (pt) combinações de ligantes de adrenoceptor alfa-2 e receptor sigma
EA201390653A1 (ru) Aa антагонисты как усилители когнитивной и моторной функций
MX2018006409A (es) Articulo que contiene celulosa, biotecnologicamente producida, para uso dermatologico.
WO2014110163A3 (en) Melk regulation for the treatment of breast cancer
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2377 DE 26-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.